The Swine Flu Play
Jul 30th, 2009 | By Ted Peroulakis | Category: Stock Market InvestingIn June, the World Health Organization (WHO) alerted the public that a worldwide pandemic of swine flu (H1N1) was sweeping the globe. Health officials at the Centers for Disease Control and Prevention (CDC) have stated that the swine flu virus could infect up to 40% of Americans over the next couple of years. At last count, the CDC said there are 43,771 swine flu cases that have been reported in America, and 302 deaths have been associated with the disease.
Many medical experts say that washing your hands with soap and water or an alcohol–based hand sanitizer are the most effective means of minimizing the spread of the swine flu.
I have been researching a small company focused on the development of pharmaceuticals for the treatment of cancer, cardiovascular, autoimmune diseases and viral infections. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is presently conducting trials for a new flu treatment called Peramivir that is said to be more effective than Tamiflu. Currently, the drug Tamiflu is the preferred treatment for swine flu. On July 17th BioCryst Pharmaceuticals released positive results from two Phase III studies of intravenous Peramivir in patients with seasonal influenza.
If Peramivir proves to be effective in fighting seasonal influenza it could quickly become the leading anti-viral treatment for the flu. And, BioCryst stock should head much higher if Peramivir is included in any national stockpiles of swine flu treatments.
Buying BioCryst stock is a speculative endeavor because its Peramivir drug has not been fully approved. Please keep in mind that BioCryst is an extremely high-risk trade, as the stock is up 1,100% since November of 2008.
BioCryst Pharmaceuticals Inc. (BCRX) will announce its second quarter 2009 financial results today, July 30, 2009. If you wish to purchase shares, you should wait until after the earnings announcement to avoid any possible downside surprises.
Best Wishes,
Ted Peroulakis
Advertisement
They've led you to believe that investors who want outsized gains must take on ridiculous risks.
Click here to learn how a Small One-Time Investment Could Grow Until It's Larger Than All of Your Other Investments Combined.
Ted Peroulakis, MBA graduated from Florida State University and received a Bachelor of Science in Finance. He has also earned his MBA from the University of Miami. Ted has over 14 years of experience in the financial industry and he is a top performing options trader and financial analyst. He was trained in the World Trade Center by Morgan Stanley Dean Witter and gained financial market experience as a stock broker on Wall Street. Ted is a contributor to the Investor’s Daily Edge.
